Haemonetics Corporation $HAE Stock Holdings Lessened by Heartland Advisors Inc.

Heartland Advisors Inc. reduced its stake in shares of Haemonetics Corporation (NYSE:HAE) by 38.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 96,125 shares of the medical instruments supplier’s stock after selling 60,413 shares during the quarter. Heartland Advisors Inc. owned approximately 0.20% of Haemonetics worth $4,685,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HAE. EverSource Wealth Advisors LLC lifted its position in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 567 shares during the last quarter. Byrne Asset Management LLC acquired a new position in shares of Haemonetics in the third quarter worth $42,000. Hantz Financial Services Inc. boosted its position in Haemonetics by 792.1% during the third quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 998 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in Haemonetics in the second quarter valued at about $64,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Price Performance

NYSE HAE opened at $58.58 on Wednesday. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a fifty day simple moving average of $73.40 and a 200 day simple moving average of $64.21. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. The company has a market cap of $2.72 billion, a P/E ratio of 16.14, a P/E/G ratio of 1.21 and a beta of 0.28.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The firm had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the previous year, the business earned $1.19 EPS. The business’s revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, sell-side analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on HAE. BTIG Research reaffirmed a “buy” rating and set a $88.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Mizuho reduced their target price on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a research note on Friday, February 6th. JPMorgan Chase & Co. increased their price target on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Finally, Citigroup cut their price target on shares of Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.44.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.